During the call, Daré discussed updates on their over $20 million nondilutive funding and their commitment to advancing women's health pharmaceutical products. They highlighted their focus on innovative treatments across various health areas and the progress of their late-stage candidates like Ovaprene and Sildenafil Cream.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing